NEW YORK (GenomeWeb News) – Medical imaging and diagnostics products firm Hologic said today that it will acquire Third Wave Technologies for $11.25 per share, or approximately $580 million.
 
The acquisition will provide Hologic with complementary products targeted to the women’s health and diagnostics market. The Bedford, Mass.-based firm sells the ThinPrep pap test, while Madison, Wis.-based Third Wave recently filed for US Food and Drug Administration clearance for two molecular diagnostic tests for human papillomavirus.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.